Claims for Patent: 11,484,534

Summary for Patent: 11,484,534

Title:	Methods for treating HCV
Abstract:	The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents to a subject with HCV infection, wherein the treatment lasts for 12 weeks and does not include administration of either interferon or ribavirin, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof.
Inventor(s):	Walid M. Awni, Barry M. Bernstein, Andrew L. Campbell, Sandeep Dutta, Chih-Wei Lin, Wei Liu, Rajeev M. Menon, Sven Mensing, Thomas J. Podsadecki, Tianli Wang
Assignee:	AbbVie Inc
Application Number:	US15/431,906
Patent Claims:	1. A method of curing hepatitis C virus (HCV) infection in a treatment naive patient infected with HCV genotype 1, 2, 3, 4, 5 or 6, the method comprising: orally administering a combination of two direct acting antiviral agents (DAAs) once daily for 8 weeks to said patient, wherein said combination of two DAAs comprises: (1) 300 mg Compound and (2) 120 mg Compound 2 2. A method of curing hepatitis C virus (HCV) infection in a treatment experienced patient infected with HCV genotype 1, 2, 4, 5 or 6, the method comprising: orally administering a combination of two direct acting antiviral agents (DAAs) once daily for 12 weeks to said patient, wherein said combination of two DAAs comprises: (1) 300 mg Compound 1 and (2) 120 mg Compound 2 3. A method of curing hepatitis C virus (HCV) infection in a treatment experienced patient infected with HCV genotype 1 or 3, the method comprising: orally administering a combination of two direct acting antiviral agents (DAAs) once daily for 16 weeks to said patient, wherein said combination of two DAAs comprises: (1) 300 mg Compound 1 and (2) 120 mg Compound 2 4. A method of curing hepatitis C virus (HCV) infection in a treatment experienced patient without cirrhosis infected with HCV genotype 1, 2, 4, 5 or 6, the method comprising: orally administering a combination of two direct acting antiviral agents (DAAs) once daily for 8 weeks to said patient, wherein said combination of two DAAs comprises: 300 mg Compound and (2) 120 mg Compound 2 5. The method of claim 2, wherein said patient is infected with HCV genotype 1 and is without cirrhosis. 6. The method of claim 5, wherein said patient was previously treated with an NS3 or NS4A inhibitor. 7. The method of claim 2, wherein said patient is infected with HCV genotype 1 and is with compensated cirrhosis. 8. The method of claim 7, wherein said patient was previously treated with an NS3 or NS4A inhibitor. 9. The method of claim 2, wherein said patient is infected with HCV genotype 1, 2, 4, 5 or 6 and is with compensated cirrhosis. 10. The method of claim 9, wherein said patient was previously treated with pegylated interferon/ribavirin. 11. The method of claim 3, wherein said patient is infected with HCV genotype 1 and is without cirrhosis. 12. The method of claim 11, wherein said patient was previously treated with an NS5A inhibitor. 13. The method of claim 3, wherein said patient is infected with HCV genotype 1 and is with compensated cirrhosis. 14. The method of claim 13, wherein said patient was previously treated with an NS5A inhibitor. 15. The method of claim 3, wherein said patient is infected with HCV genotype 3 and is without cirrhosis. 16. The method of claim 15, wherein said patient was previously treated with pegylated interferon/ribavirin 17. The method of claim 3, wherein said patient is infected with HCV genotype 3 and is with compensated cirrhosis. 18. The method of claim 17, wherein said patient was previously treated with pegylated interferon/ribavirin. 19. The method of claim 4, wherein said patient was previously treated with pegylated interferon/ribavirin. 20. The method of claim 1, wherein the patient achieves a sustained virologic response at 24 weeks post-treatment (SVR24). 21. The method of claim 2, wherein the patient achieves a sustained virologic response at 24 weeks post-treatment (SVR24). 22. The method of claim 3, wherein the patient achieves a sustained virologic response at 24 weeks post-treatment (SVR24). 23. The method of claim 4, wherein the patient achieves a sustained virologic response at 24 weeks post-treatment (SVR24).